Introduction
============

Despite years of successful combination antiretroviral therapy (cART), viral replication rebounds almost inevitably in all HIV infected individuals upon cART cessation ([@B21]; [@B54]; [@B86]). This is due to the presence of persistent viral reservoirs which are the greatest barrier to an HIV cure. Because of the relative ease with which peripheral blood can be collected, this is the most common anatomical compartment analyzed in clinical HIV studies ([@B4], [@B2], [@B3]; [@B28], [@B27]; [@B67]; [@B76]; [@B59]; [@B75]; [@B36]; [@B49]; [@B80], [@B81]; [@B72]; [Table 1](#T1){ref-type="table"}). However, it is known that HIV (and SIV in non-human primates) persists in multiple organ systems throughout the body during cART and that peripheral blood reservoir findings may not accurately reflect reservoirs in tissue ([@B20]; [@B45]; [@B70], [@B71]; [@B29]; [@B61]). Thus, it is essential that the impacts of curative strategies in all relevant organ systems be defined.

###### 

Overview of tissue analyses in clinical studies dosing small molecule interventions in HIV cure-related context.

  **Drug class**                     **Drug**         **Trial identifier**   **Intervention**                                                       **Tissues (other than peripheral blood) examined and analyses performed**                                                                                                                                                                                                                 **Primary study citation**   **Sub-study citations**
  ---------------------------------- ---------------- ---------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- -----------------------------------------------------------------------
  Histone deacetylase inhibitors     Vorinostat       NCT01319383            Single dose of vorinostat                                              No other tissues examined                                                                                                                                                                                                                                                                 [@B4]                        [@B87]
                                                                             22 cyclical doses of vorinostat over 12--16 weeks                      No other tissues examined                                                                                                                                                                                                                                                                 [@B2]                        [@B87]; [@B32]
                                                                             Up to 10 doses of vorinostat given at 72-h intervals                   No other tissues examined                                                                                                                                                                                                                                                                 [@B3]                        [@B87]
                                                      NCT01365065            Daily vorinostat for 14 days                                           Rectal biopsies: CA US HIV RNA^\#^; HIV DNA; T cell activation                                                                                                                                                                                                                            [@B28]                       [@B58]
                                     Panobinostat     NCT01680094            Panobinostat dosed three times per week every other week for 8 weeks   [Cerebral Spinal Fluid]{.ul} : HIV RNA; levels of biomarkers of neurodegeneration [Sigmoid Biopsies]{.ul} : HIV DNA; T cell activation; T cell cytokine production; virus clonality                                                                                                       [@B67]                       [@B15]; [@B37]; [@B63]; [@B68]; [@B7]; [@B47]; [@B87]; [@B12]; [@B32]
                                     Romidepsin       NCT02092116            3 romidepsin infusions once weekly for 3 weeks                         No other tissues examined                                                                                                                                                                                                                                                                 [@B75]                       [@B42]
                                                                             6-Vacc4x^Δ^ immunizations followed by 3 romidepsin infusions           No other tissues examined                                                                                                                                                                                                                                                                 [@B49]                       [@B78]; [@B42]
  Aldehyde Dehydrogenase Inhibitor   Disulfiram       NCT01286259            Daily disulfiram for 14 days                                           No other tissues examined                                                                                                                                                                                                                                                                 [@B76]                       None indexed in PubMed
                                                      NCT01944371            3-day course of disulfiram                                             No other tissues examined                                                                                                                                                                                                                                                                 [@B27]                       [@B46]
                                                      NCT01571466            3 immunizations of MVA-B^∗^ ± 3 months once daily disulfiram           No other tissues examined                                                                                                                                                                                                                                                                 [@B59]                       None indexed in PubMed
  PKC^‡^ Agonist                     Bryostatin-1     NCT02269605            Single dose of bryostatin-1                                            No other tissues examined                                                                                                                                                                                                                                                                 [@B36]                       None Indexed in Pubmed
  TLR3^§^ agonist                    Poly-ICLC^‡⁣‡^   NCT02071095            2 consecutive daily doses                                              No other tissues examined                                                                                                                                                                                                                                                                 [@B72]                       None indexed in PubMed
  TLR9^§§^ Agonist                   MGN1703          NCT02443935            Twice-weekly dosing for 4 weeks                                        [Sigmoid Biopsies]{.ul} : HIV DNA; T cell activation; microbiome diversity; RNASeq, IHC^†^ for interferon response                                                                                                                                                                        [@B80]                       [@B44]
                                                                             Twice-weekly dosing for 24 weeks                                       [Inguinal Lymph Nodes]{.ul} : CA US HIV RNA^\#^; HIV DNA; immune cell activation; B cell differentiation and maturation; antibody production, glycan status and HIV-specificity; RNASeq; IHC^†^ for interferon response; IF^†⁣†^ for follicles; ISH^†⁣†⁣†^ for HIV RNA; virus clonality   [@B81]                       [@B73]; [@B82]
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CA US HIV RNA: Cell-associated unspliced HIV RNA;

Δ

Vacc-4x: a synthetic p24 gag peptide vaccine;

∗

MVA-B: modified vaccinia Ankara-based HIV-1 vaccine;

‡

PKC: Protein kinase C;

‡⁣‡

Poly-ICLC: Polyinosinic-polycytidylic acid, and poly-L-lysine;

§

TLR3: Toll-like receptor 3;

§§

TLR9: Toll-like receptor 9;

†

IHC: Immunohistochemistry;

†⁣†

IF: Immunofluorescence;

†⁣†⁣†

ISH:

In situ

hybridization

There are many unanswered questions regarding the impacts of HIV cure-related interventions on systemic HIV persistence. Among these are: Do findings in peripheral blood reflect outcomes in other tissues like the intestines and lymph nodes? and Do persistent viruses move freely between anatomical compartments? Studies have indicated that compartmentalization of HIV-infected cells into specific anatomical compartment and/or immunological sanctuaries occurs in untreated infections and that this compartmentalization persists during suppressive cART ([@B9]). In addition, some of the drugs that have been tested in HIV cure trials may have reduced penetration into these compartments which may impede HIV cure efforts ([@B8]; [@B68]). Therefore, we have focused this review on the impacts of HIV cure-related strategies onto clinical studies dosing small molecule interventions \[e.g., histone deacetylase inhibitors, PKC agonist, disulfiram and *toll*-like receptor (TLR) agonists\] and examining HIV persistence in tissues. Specifically, we review the impacts of such interventions on mechanisms that regulate HIV persistence *in vivo* as well as the immunological and virological impacts of these interventions in tissues other than peripheral blood. Other HIV cure related interventions including gene therapy approaches, stem cell transplants, antiretroviral intensification, therapeutic vaccines and broadly neutralizing antibody infusions have recently been reviewed elsewhere ([@B66]; [@B13]). Similarly, we callout several key animal model findings but do not elaborate upon animal model studies of HIV cure-related interventions as these data have also recently been reviewed elsewhere ([@B57]; [@B25]; [@B64]; [@B60]; [@B38]; [@B83]).

Effects of HIV Cure Interventions in the Central Nervous System, Intestines, and Lymph Nodes
============================================================================================

We and others have made efforts to complement peripheral blood analyses by defining the effects of various HIV cure-related interventions on HIV persistence within key tissues. In these trials, the intervention were either suberoylanilide hydroxamic acid (SAHA), panobinostat or the TLR9 agonist MGN1703 ([@B28]; [@B67]; [@B80], [@B81]). In the trial exploring SAHA as a latency reversing agent (LRA), the Lewin group examined rectal tissue biopsies ([@B28]). In our panobinostat trial, we examined cerebral spinal fluid and sigmoid biopsies ([@B15]; [@B68]). And in our MGN1703 trials, we examined sigmoid biopsies and lymph nodes ([@B44]; [@B73]). All these anatomical reservoir studies were longitudinal in design as they included analyses of samples at baseline as well as near the end of the dosing period for the interventional drug in the respective study.

Human and animal study data highlight the potential for the central nervous system to function as an HIV reservoir or sanctuary site for the virus during treatment ([@B19]; [@B6]; [@B17]; [@B90]; [@B65]; [@B34]; [@B40], [@B39]). Investigators have examined the toxicity and latency reversal effects of multiple agents including panobinostat and romidepsin on primary astrocytes *ex vivo* ([@B33]). These agents were found to be non-toxic and capable of inducing viral transcription at therapeutic concentrations. Our study provides the only published *in vivo* human data on central nervous system effects of a latency reversal agent to date ([@B68]). We found that repeated, cyclic treatment with panobinostat did not lead to central nervous system adverse effects according to cerebral spinal fluid biomarkers of inflammation and neurodegeneration. We also found that panobinostat did not sufficiently penetrate the central nervous system to detectable levels and that there were no treatment-associated changes in HIV reservoir detection in the cerebral spinal fluid ([@B68]). This study represents a single foray into determining the *in vivo* effects of HIV cure interventions in the cerebral spinal fluid for one intervention. However, this finding may not be specific for panobinostat since it has been shown in non-human primates that the concentration of another latency reversal agent romidepsin in cerebral spinal fluid is only approximately 2% of the level found in plasma ([@B8]). Given the scarcity of data, drawing conclusions about distinct HIV cure-related intervention impacts in the central nervous system is premature.

The role of intestines in HIV persistence has been researched extensively in humans as well as non-human primates ([@B1]; [@B35]; [@B11]; [@B56]; [@B50]; [@B55]; [@B79]; [@B16]; [@B18]; [@B62]; [@B88], [@B89]; [@B14]; [@B48]; [@B30]; [@B41]; [@B43]; [@B22]; [@B29]). In a clinical study of 14 days of repeated administration of the histone deacetylase inhibitor SAHA, HIV RNA levels in rectal CD4 + T cells were modestly increased and HIV DNA levels were unchanged ([@B28]). This outcome was also realized in our studies of the sigmoid colon during panobinostat as well as MGN1703 dosing given that we did not observe cohort wide changes in the size of the HIV reservoir in either study ([@B15]; [@B44]). While SAHA had no impact on T cell activation in rectal tissue, panobinostat dosing was associated with a decreased frequency of CD69+ intestinal T cells ([@B28]; [@B15]). This was in contrast to findings in peripheral blood where T cell activation (CD69+) was found to be increased following the first doses of panobinostat ([@B12]). Additionally, we observed that panobinostat increased IL-17A expression in the intestinal epithelium and IL-17a is known to induce the production of antimicrobial peptides that may help to maintain the intestinal epithelial barrier which is damaged during HIV infection ([@B10]; [@B51]; [@B15]). With dosing of the TLR9 agonist MGN1703, a robust interferon response was noted in the sigmoid colon ([@B44]). This interferon response in the intestine was quite distinct from that observed in the peripheral blood of the same individuals ([@B80]). Specifically, we observed that both type I and type II interferons were generated in the periphery of treated individuals but only a type I interferon response was detected in the sigmoid colon. The type I interferon response in the colon was associated with a trend toward improved intestinal microbiome species composition. Furthermore, we found that higher baseline levels of TLR9 expression in the intestine was associated with greater reductions in levels of integrated HIV DNA during MGN1703 treatment ([@B44]). This result suggests that tissue-specific biomarkers may help determine which individuals will exhibit the strongest response to HIV cure-related interventions in future studies. Overall, these analyses examining the intestines of participants taking HIV cure-related interventions show that the intestines are an important anatomical site for study as the peripheral blood and intestines did not always exhibit similar responses to treatment in the examined parameters. Future studies will benefit from incorporating comprehensive intestinal biopsy analyses into the study plan.

The importance of lymphoid tissues, particularly lymph nodes, in HIV persistence is clear ([@B74]; [@B26]; [@B31]; [@B5]; [@B24]; [@B52]; [@B29]). Beyond the observation that lymph node tissues showed no changes in SIV reservoirs in non-human primates given SAHA ([@B23]), there has been no published data on the impacts of HIV cure-related interventions *in vivo* in lymph node tissues. To begin addressing this major knowledge gap in the field, we undertook a longitudinal study of inguinal lymph nodes in participants taking the TLR9 agonist MGN1703 for 24 weeks ([@B73]). We found that lymph nodes exhibited a potent interferon response to MGN1703 dosing as was observed in peripheral blood ([@B81]). We also observed similarities between the lymph nodes and peripheral blood regarding significant changes in B cell differentiation and maturation levels in response to TLR9 agonist treatment. Related to these observations, we found that MGN1703 increased plasma IgG levels as well as increased AID expression in lymph nodes ([@B73]). Furthermore, after 24 weeks of MGN1703 dosing, plasma and lymph node IgG glycosylation patterns were significantly altered. Changes in glycosylation were associated with reductions in viral reservoir. This study revealing similarities between the peripheral blood and lymph node responses to MGN1703 is a beginning in the process of understanding the lymphoid tissue effects of HIV cure-related interventions.

No Evidence of Viral Compartmentalization in TLR9 Agonist Therapy Trial
=======================================================================

While the direct *in vivo* impacts of HIV cure-related clinical interventions on latency controlling mechanisms have not been fully elucidated, there are multiple analyses that have focused on determining whether such interventions impact only clonal HIV isolates or reactivate a broad spectrum of persistent HIV isolates. These phylogenetic analyses performed with clinical trial samples have revealed that the histone deacetylase inhibitors SAHA, panobinostat and romidepsin reactivate latent viruses with unique sequence signatures as well as families of virus clones ([@B7]; [@B84], [@B85]). The panobinostat study also provided the first *in vivo* observation of a tissue-derived cell (i.e., a sigmoid colon lamina propria mononuclear cell) harboring an HIV provirus that matched plasma-derived rebound viruses isolated following analytical treatment interruption ([@B7]). Thus, these HIV cure-related interventions have broad latency reversing capacity *in vivo* in HIV infected individuals.

We recently examined the clonality of persistent virus in lymph nodes and compared these sequences to replication competent viruses that rebounded during an analytical treatment interruption ([@B82]). We examined samples from our clinical trial in which participants received 24 weeks of repeated TLR9 agonist treatment. When we compared the latent viruses obtained from CD4+ T cells in peripheral blood and lymph nodes to viruses emerging during treatment interruption, we found there was no overlap between latent reservoir and rebound sequences. This was true even though 98% of intact or replication competent clonal sequences overlapped between these two anatomical compartments. Although rebound viruses were not derived from reservoirs detected in either blood or lymph node, we were able to show that rebound viruses were generated by recombination events between viruses within these two compartments ([@B82]). This observation is consistent with peripheral blood data showing that recombination events are important during the emergence of rebound viremia ([@B53]). Whether the recombination events are due to improved viral fitness or escape of immune pressure is not yet known ([@B77]; [@B69]). Overall, these data indicate that CD4+ T cells harboring latent HIV circulate between blood and lymphoid tissues during cART.

Conclusion
==========

Understanding the regulation of HIV reservoir persistence is a high priority in the HIV cure research field. Since 2012, 14 HIV cure-related clinical trials have been published where the objective was to test the impacts of small molecule interventions designed to either cause infected cells to become visible to the immune system for clearance or to improve the ability of the immune system to clear infected cells. These clinical studies have yielded new insights into the effects of the interventions on the regulation of HIV persistence, particularly related to clonal populations of latently infected cells. In four of the trials, efforts were made to define the impacts of the respective intervention in the central nervous system, intestinal tissues and/or lymph nodes. Data from these four trials reveal key similarities between the peripheral blood and the organs. Furthermore, they highlight that observations made in peripheral blood are not always fully representative of the impacts made by interventions in the organs which also harbor persistent HIV reservoirs. Such differential responses highlight the importance of defining the impacts of curative strategies in all relevant organ systems including those reviewed herein as well as other applicable tissues such as spleen and bone marrow. With improved methods for analyzing tissue reservoirs, investigators will begin to overcome the limitations in studies that are due to the extreme rarity and heterogeneity of HIV infected cells *in vivo* in the setting of cART. Advancement of the HIV cure research agenda will benefit from a continued push to seek detailed explorations of infected cells both derived from peripheral blood as well as from organ sources. Thus, there is strong impetus to continue examining multiple organs in such trials.
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